Restoration of erectile function by suppression of corporal apoptosis and oxidative stress with losartan in aged rats with erectile dysfunction.
age-related erectile dysfunction
apoptosis
fibrosis
losartan
oxidative stress
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
31
08
2018
revised:
12
03
2019
accepted:
14
01
2020
pubmed:
23
1
2020
medline:
26
5
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
The prevalence of erectile dysfunction (ED) increases progressively with age, but its potential pathophysiology has not been fully demonstrated. Hence, this article was aimed to identify the functional and morphological characterization of the corpus cavernosum in aged rats and to evaluate the effects of the Angiotensin II type 1 receptor antagonist losartan on age-related ED (AED). A total of 40 young and aged Sprague Dawley rats were randomly divided into four groups (n = 10 per group): young rats as normal controls (YNC) group; aged rats with normal erectile function (ANC) group; aged rats with ED (AED) group; and a losartan-treated AED (AED + Losartan) group. The treated group received losartan (30 mg/kg) once daily oral gavage for 4 weeks. Erectile function was measured by the ratio of peak intracavernous pressure (ICP)/mean arterial pressure (MAP), and relevant tissues were harvested for transmission electron microscopy, Immunohistochemistry, Masson's trichrome staining, TUNEL, caspase-3 activity assay and Western blot. The AED group exhibited decreases in erectile response and increases in the role of apoptosis, fibrosis as well as oxidative stress, compared with the control groups. After daily administration of losartan for four weeks, it could slightly restore erectile function and significantly attenuate corporal apoptosis, fibrosis, and oxidative stress of AED. However, the result was still not comparable with that of the control groups. Moreover, the expression levels of p-Bad/Bad and p-AKT/AKT were significantly lower, whereas the expression levels of Bax/Bcl-2, Nrf2/Keap-1, Fibronectin, HO-1, and caspase-3 activity were significantly higher in the AED groups and while losartan could significantly attenuate these changes of AED, it was still not comparable with that of the control groups. Our results indicated that administration of losartan not merely restored erectile function, but also significantly prevented corporal apoptosis and oxidative stress in AED by suppressing the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 pathways.
Sections du résumé
BACKGROUND
The prevalence of erectile dysfunction (ED) increases progressively with age, but its potential pathophysiology has not been fully demonstrated. Hence, this article was aimed to identify the functional and morphological characterization of the corpus cavernosum in aged rats and to evaluate the effects of the Angiotensin II type 1 receptor antagonist losartan on age-related ED (AED).
MATERIAL AND METHODS
A total of 40 young and aged Sprague Dawley rats were randomly divided into four groups (n = 10 per group): young rats as normal controls (YNC) group; aged rats with normal erectile function (ANC) group; aged rats with ED (AED) group; and a losartan-treated AED (AED + Losartan) group. The treated group received losartan (30 mg/kg) once daily oral gavage for 4 weeks. Erectile function was measured by the ratio of peak intracavernous pressure (ICP)/mean arterial pressure (MAP), and relevant tissues were harvested for transmission electron microscopy, Immunohistochemistry, Masson's trichrome staining, TUNEL, caspase-3 activity assay and Western blot.
RESULTS
The AED group exhibited decreases in erectile response and increases in the role of apoptosis, fibrosis as well as oxidative stress, compared with the control groups. After daily administration of losartan for four weeks, it could slightly restore erectile function and significantly attenuate corporal apoptosis, fibrosis, and oxidative stress of AED. However, the result was still not comparable with that of the control groups. Moreover, the expression levels of p-Bad/Bad and p-AKT/AKT were significantly lower, whereas the expression levels of Bax/Bcl-2, Nrf2/Keap-1, Fibronectin, HO-1, and caspase-3 activity were significantly higher in the AED groups and while losartan could significantly attenuate these changes of AED, it was still not comparable with that of the control groups.
CONCLUSIONS
Our results indicated that administration of losartan not merely restored erectile function, but also significantly prevented corporal apoptosis and oxidative stress in AED by suppressing the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 pathways.
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Losartan
JMS50MPO89
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
769-779Informations de copyright
© 2020 American Society of Andrology and European Academy of Andrology.
Références
Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50-56.
Shamloul R, Ghanem H. Erectile dysfunction. Lancet (London, England). 2013;381(9861):153-165.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463.
Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sexual Med. 2010;7(4 Pt 2):1598-1607.
Nicolosi A, Laumann EO, Glasser DB, Moreira ED Jr, Paik A, Gingell C. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology. 2004;64(5):991-997.
Albersen M, Orabi H, Lue TF. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology. 2012;58(1):3-14.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61.
Ferrini MG, Hlaing SM, Chan A, Artaza JN. Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat. Andrology. 2015;4(1).
Bivalacqua TJ, Armstrong JS, Biggerstaff J, et al. Gene transfer of extracellular SOD to the penis reduces O2-* and improves erectile function in aged rats. Am J Physiol Heart Circ Physiol. 2003;284(4):H1408-H1421.
Numao N, Masuda H, Sakai Y, Okada Y, Kihara K, Azuma H. Roles of attenuated neuronal nitric-oxide synthase protein expression and accelerated arginase activity in impairing neurogenic relaxation of corpus cavernosum in aged rabbits. BJU Int. 2007;99(6):1495-1499.
Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. FASEB Journal. 2006;20(3):536-538.
Aversa A, Bruzziches R, Francomano D, Natali M, Gareri P, Spera G. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol. 2010;17(1):38-47.
Canguven O, Lagoda G, Sezen SF, Burnett AL. Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats. J Urol. 2009;181(6):2816-2822.
Zhang Y, Jia L, Zhang Y, Ji W, Li H. Angiotensin II silencing alleviates erectile dysfunction through down-regulating the Rhoa/Rho kinase signaling pathway in rats with diabetes mellitus. Cell Physiol Biochem. 2018;45(1):419-427.
Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol. 1997;157(5):1920-1925.
Li WJ, Xu M, Gu M, et al. Losartan preserves erectile function by suppression of apoptosis and fibrosis of corpus cavernosum and corporal veno-occlusive dysfunction in diabetic rats. Cell Physiol Biochem. 2017;42(1):333-345.
Toblli JE, Cao G, Lombrana A, Rivero M. Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. J Sex Med. 2007;4(5):1291-1303.
Cho MC, Park K, Kim SW, Paick JS. Restoration of erectile function by suppression of corporal apoptosis, fibrosis and corporal veno-occlusive dysfunction with rho-kinase inhibitors in a rat model of cavernous nerve injury. J Urol. 2015;193(5):1716-1723.
Liu W, Du Y, Liu J, et al. Effects of atrazine on the oxidative damage of kidney in Wister rats. Int J Clin Exp Med. 2014;7(10):3235-3243.
Pan F, Qiu XF, Yu W, et al. MicroRNA-200a is up-regulated in aged rats with erectile dysfunction and could attenuate endothelial function via SIRT1 inhibition. Asian J Androl. 2016;18(1):74-79.
Pan F, Xu J, Zhang Q, et al. Identification and characterization of the MicroRNA profile in aging rats with erectile dysfunction. J Sex Med. 2014;11(7):1646-1656.
Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol. 2004;171(1):495-500.
Ruan Y, Li M, Wang T, et al. Taurine supplementation improves erectile function in rats with streptozotocin-induced type 1 diabetes via amelioration of penile fibrosis and endothelial dysfunction. J Sex Med. 2016;13(5):778-785.
Li WJ, Zhou J, Li B, Wang H, Peng YB, Wang Z. PARP inhibition restores erectile function by suppressing corporal smooth muscle apoptosis in diabetic rats. J Sex Med. 2011;8(4):1072-1082.
Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002;14(6):466-471.
Liu J, Zhou F, Li GY, et al. Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats. Int J Mol Sci. 2013;14(5):10661-10673.
Qiu X, Sun C, Yu W, et al. Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes-associated erectile dysfunction. J Androl. 2012;33(1):37-44.
Li H, Chen L, Wang T, Wang S, Liu J. The effect of cavernous nerve traction on erectile function in rats. PLoS ONE. 2017;12(10):e0186077.
Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sexal Med. 2010;7(1 Pt 2):445-475.
Tirado LCE, Ferrer JE, Herrera AM. Aging and erectile dysfunction. Sex Med Rev. 2016;4(1):63-73.
Tang Z, Cui K, Luan Y, Ruan Y, Wang T, Yang J, Wang S, Liu J, Wang D. Human tissue kallikrein 1 ameliorates erectile function via modulation of macroautophagy in aged transgenic rats. Andrology. 2018;6(5):766-774.
Ferrini M, Magee TR, Vernet D, Rajfer J, Gonzálezcadavid NF. Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol Reprod. 2001;64(3):974-982.
Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal. 2013;19(10):1085.
Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol. 2012;44(3):465-468.
Kilarkaje N, Yousif MHM, El-Hashim AZ, Makki B, Akhtar S, Benter IF. Role of angiotensin II and angiotensin-(1-7) in diabetes-induced oxidative DNA damage in the corpus cavernosum. Fertil Steril. 2013;100(1):226-233.
Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F. Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol. 2004;24(6):614-623.
Daniel C. Blocking of angiotensin II is more than blocking of transforming growth factor-β. Kidney Int. 2008;74(5):551-553.
Ferrini MG, Kovanecz I, Sanchez S, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76(5):915-923.
Luan Y, Ruan Y, Wang T, et al. Preserved erectile function in the aged transgenic rat harboring human tissue kallikrein 1. J Sex Med. 2016;13(9):1311-1322.
Park K, Shin JW, Oh JK, Ryu KS, Kim SW, Paick JS. Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1. J Androl. 2005;26(1):123-128.
Li WJ, Wang H, Zhou J, et al. P144, A TGF-β1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats. J Sex Med. 2013;10(12):2942.
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109.